文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

评估N-乙酰半胱氨酸与造影后急性肾损伤关联的Meta分析技术:系统评价与Meta分析

Meta-analytic Techniques to Assess the Association Between N-acetylcysteine and Acute Kidney Injury After Contrast Administration: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2022-07-01
一句话结论101项RCT的Meta分析显示,N-乙酰半胱氨酸(NAC)预防造影剂急性肾损伤(CI-AKI)的汇总OR为0.72(随机效应模型)或0.82(固定效应模型),但存在显著异质性和发表偏倚,仅限制于大样本RCT或临床结局时效应消失。

该研究系统检索了截至2020年1月的文献,纳入101项比较NAC与安慰剂或其他预防药物预防CI-AKI的RCT。随机效应模型汇总OR为0.72(95%CI 0.63-0.82),固定效应模型OR为0.82(95%CI 0.76-0.90),但异质性显著(I²=37.6,P<.001)且存在发表偏倚,仅在限制于大样本RCT(N≥500)时发表偏倚减少。肾脏替代治疗需求和死亡率等临床结局异质性小、无发表偏倚,汇总结果均为中性。结论提示标准Meta分析技术可能产生虚假关联。

要点

  • 纳入101项RCT,中位样本量112例(范围20-4993),仅3项样本量≥500例。
  • NAC预防CI-AKI的随机效应模型汇总OR为0.72(95%CI 0.63-0.82),固定效应模型OR为0.82(95%CI 0.76-0.90)。
  • 存在显著异质性(I²=37.6,P<.001)和显著发表偏倚,限制于大样本RCT(N≥500)后发表偏倚减少。
  • 肾脏替代治疗需求(45项试验)和死亡率(41项试验)异质性小、无发表偏倚,汇总结果均为中性。

适用人群与场景

  • 成人中比较NAC与任何其他预防药物或安慰剂预防造影剂急性肾损伤(CI-AKI)的随机临床试验(RCT)。

研究设计与关键结果

  • 研究设计:系统评价与Meta分析,检索Medline、Embase和Cochrane Central Register of Controlled Trials数据库,纳入英文发表的RCT,检索时间从数据库建库至2020年1月。
  • 共纳入101项RCT,中位样本量112例(范围20-4993);29项试验样本量≥200,仅3项试验样本量≥500。
  • 45项试验报告肾脏替代治疗需求,41项试验报告死亡率。
  • NAC似乎显示获益:随机效应模型汇总OR为0.72(95%CI 0.63-0.82),固定效应模型汇总OR为0.82(95%CI 0.76-0.90)。
  • 存在显著异质性(I²=37.6,P<.001)和显著发表偏倚,仅在限制于大样本RCT(N≥500)时发表偏倚减少。
  • 临床结局(肾脏替代治疗需求和死亡率)异质性小、无发表偏倚,各自提供稳健的中性汇总结果。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(纳入RCT)。
  • 局限:存在显著发表偏倚和其他偏倚,标准Meta分析技术导致显著异质性和虚假关联,即使使用随机效应模型;原文未报告其他具体局限性。

对床旁实践的改变

  • 原文结论提示,标准Meta分析技术可能产生虚假关联,当分析限制于大样本RCT或临床结局时效应更稳健且为中性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The most suitable analytic method to systematically analyze numerous trials with contradictory results is unclear. Multiple trials assessing the use of N-acetylcysteine (NAC) for prevention of contrast-induced acute kidney injury (CI-AKI) have had contradictory results with recent trials confirming a lack of benefit.

OBJECTIVE: To systematically review the literature on NAC for the prevention of CI-AKI, and to explore the heterogeneity, publication bias, and small-study effect to determine the most suitable analytic method in a setting where the literature is contradictory.

DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials databases were used to find randomized clinical trials (RCTs) comparing NAC with any other prophylactic agent or placebo in adults.

STUDY SELECTION: The search included studies published in English from database inception to January 2020. Two independent reviewers screened the studies, extracted data, and performed the risk of bias assessment.

DATA EXTRACTION AND SYNTHESIS: A meta-analysis was conducted about the effect of NAC on CI-AKI, the need for dialysis, and mortality. Fixed and random effects analyses were also performed. Funnel plots and the trim and fill method were used for assessment of publication bias. Metaregression was performed to explore the heterogeneity and subgroup analysis to examine the association between NAC and CI-AKI when studies were categorized according to sample size and number of events.

RESULTS: A total of 101 trials were included in this meta-analysis. The median sample size was 112 (range, 20 to 4993). Twenty-nine trials had a sample size of 200 or more, and only 3 trials had a sample size of 500 or more. Forty-five trials reported the need for kidney replacement therapy, and 41 trials reported mortality as an outcome. NAC seemed to show a benefit, with a pooled OR of 0.72 (95% CI, 0.63-0.82) using random effects model and a pooled OR of 0.82 (95% CI 0.76-0.90) using a fixed effects model. However, there was significant heterogeneity (I2 = 37.6; P < .001) and significant publication bias, which was reduced only when restricting to large RCTs (N ≥ 500). The clinical outcomes (ie, the need for kidney replacement therapy and mortality) revealed little heterogeneity and no publication bias, and each provided a robust neutral summary result.

CONCLUSIONS AND RELEVANCE: In this meta-analysis, NAC was associated with a benefit in the prevention of CI-AKI. However, because of substantial publication bias and other biases, standard meta-analytic techniques resulted in significant heterogeneity and a spurious, or factitious, association, even when using a random effects model. When the analysis was restricted to RCTs with a large sample size to account for publication bias or restricted to trials with clinical outcomes, this issue was reduced and resulted in more robust and neutral effect sizes.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Magner K, Ilin JV, Clark EG, et al. Meta-analytic Techniques to Assess the Association Between N-acetylcysteine and Acute Kidney Injury After Contrast Administration: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID: 35788669. doi:10.1001/jamanetworkopen.2022.20671

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。